
Paul Grootendorst

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8128052/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Brand drug companies impeding generic drug company access to product samples: Estimated prevalence and impact on drug costs. Journal of Generic Medicines, 2022, 18, 10-20.	0.2	1
2	The effect of patented drug price on the share of new medicines across OECD countries. Health Policy, 2022, 126, 795-801.	3.0	1
3	Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous βâ€amyloid peptide accumulation in mice. Biopharmaceutics and Drug Disposition, 2021, 42, 372-388.	1.9	6
4	Impact of a peer comparison intervention on seasonal influenza vaccine uptake in community pharmacy: A national cluster randomized study. Journal of the American Pharmacists Association: JAPhA, 2021, 61, 539-546.e5.	1.5	0
5	The health impact of delaying directâ€acting antiviral treatment for chronic hepatitis C: A decisionâ€analytic approach. Liver International, 2020, 40, 51-59.	3.9	6
6	Development and Validation of a Clinical Prediction Tool for Seasonal Influenza Vaccination in England. JAMA Network Open, 2020, 3, e207743.	5.9	2
7	Factors associated with drug shortages in Canada: a retrospective cohort study. CMAJ Open, 2020, 8, E535-E544.	2.4	13
8	Patient and practice level factors associated with seasonal influenza vaccine uptake among at-risk adults in England, 2011 to 2016: An age-stratified retrospective cohort study. Vaccine: X, 2020, 4, 100054.	2.1	35
9	The Impact of Tiered-Pricing Framework on Generic Entry in Canada. International Journal of Health Policy and Management, 2020, , .	0.9	2
10	Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet Journal of Rare Diseases, 2019, 14, 12.	2.7	68
11	Pharmacists should counsel users of medical cannabis, but should they be dispensing it?. Canadian Pharmacists Journal, 2019, 152, 10-13.	0.8	6
12	Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. BMJ Open, 2019, 9, e027491.	1.9	23
13	Medicine Prices in the United States and Canada. , 2019, , 31-43.		0
14	Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario. International Journal of Health Services, 2018, 48, 702-715.	2.5	2
15	Impact of depression and recreational drug use on emergency department encounters and hospital admissions among people living with HIV in Ontario: A secondary analysis using the OHTN cohort study. PLoS ONE, 2018, 13, e0195185.	2.5	7
16	Uptake and impact of regulated pharmacy technicians in Ontario community pharmacies. Canadian Pharmacists Journal, 2018, 151, 197-202.	0.8	4
17	Policy to encourage the development of antimicrobials. International Journal of Health Governance, 2018, 23, 101-110.	1.2	2
18	Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology. PharmacoEconomics - Open, 2017, 1, 167-173.	1.8	4

PAUL GROOTENDORST

#	Article	IF	CITATIONS
19	A comparison of mechanisms for setting generic drug prices in Canada. Journal of Generic Medicines, 2017, 13, 19-27.	0.2	6
20	Does rising income inequality affect mortality rates in advanced economies?. Economics, 2017, 11, .	0.6	0
21	Factors associated with mental health in Canadian Veterans. Journal of Military, Veteran and Family Health, 2017, 3, 41-51.	0.6	9
22	Clinical and microbiological epidemiology of early and late infectious complications among solid-organ transplant recipients requiring hospitalization. Transplant International, 2016, 29, 1029-1038.	1.6	18
23	The case for an essential medicines list for Canada. Cmaj, 2016, 188, E499-E503.	2.0	15
24	Economic evaluation of vaccines in Canada: A systematic review. Human Vaccines and Immunotherapeutics, 2016, 12, 1257-1264.	3.3	8
25	How Effective Is the Medicare Part D Drug Plan?. Annals of Internal Medicine, 2015, 162, 869-870.	3.9	1
26	The Opportunity Cost of Capital. Inquiry (United States), 2015, 52, 004695801558464.	0.9	8
27	Determinants of chronic physical health conditions in Canadian Veterans. Journal of Military, Veteran and Family Health, 2015, 1, 32-42.	0.6	5
28	Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics. International Journal of the Economics of Business, 2015, 22, 201-217.	1.7	6
29	Intended and unintended effects of restrictions on the sale of cigarillos to youth: evidence from Canada. Tobacco Control, 2015, 24, 382-388.	3.2	6
30	Cost Consequence Analysis of Implementing the Low Risk Ankle Rule in Emergency Departments. Annals of Emergency Medicine, 2015, 66, 455-463.e4.	0.6	16
31	Validation of Six Short and Ultra-short Screening Instruments for Depression for People Living with HIV in Ontario: Results from the Ontario HIV Treatment Network Cohort Study. PLoS ONE, 2015, 10, e0142706.	2.5	23
32	Canada's New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem. Healthcare Policy, 2015, 11, 10-4.	0.6	4
33	Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada. Applied Economics, 2014, 46, 1081-1092.	2.2	10
34	Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis. CMAJ Open, 2013, 1, E83-E90.	2.4	12
35	Effect of the Low Risk Ankle Rule on the frequency of radiography in children with ankle injuries. Cmaj, 2013, 185, E731-E738.	2.0	41
36	Canada's laws on pharmaceutical intellectual property: the case for fundamental reform: Figure 1:. Cmaj, 2012, 184, 543-549.	2.0	8

PAUL GROOTENDORST

#	Article	IF	CITATIONS
37	The cost of drug development: A systematic review. Health Policy, 2011, 100, 4-17.	3.0	379
38	Equity in dental care among Canadian households. International Journal for Equity in Health, 2011, 10, 14.	3.5	30
39	Economic instruments for obesity prevention: results of a scoping review and modified delphi survey. International Journal of Behavioral Nutrition and Physical Activity, 2011, 8, 109.	4.6	57
40	Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiology and Drug Safety, 2011, 20, 838-848.	1.9	27
41	New approaches to rewarding pharmaceutical innovation. Cmaj, 2011, 183, 681-685.	2.0	32
42	How should we support pharmaceutical innovation?. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 313-320.	1.4	5
43	Response to Lichtenberg. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 505-508.	1.4	0
44	Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 353-364.	1.4	23
45	Validation of a Prediction Model to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index Scores in Patients with Osteoarthritis of the Hip. Value in Health, 2008, 11, 470-477.	0.3	21
46	The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada. Health Policy, 2007, 84, 1-13.	3.0	5
47	The Effect of Pharmaceutical Patent Term Length on Research and Development and Drug Expenditures in Canada. Healthcare Policy, 2007, 2, 63-84.	0.6	6
48	Becoming the best mom that I can: women's experiences of managing depression during pregnancy – a qualitative study. BMC Women's Health, 2007, 7, 13.	2.0	27
49	A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Statistics in Medicine, 2007, 26, 734-753.	1.6	940
50	Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study. Statistics in Medicine, 2007, 26, 754-768.	1.6	185
51	A review of instrumental variables estimation of treatment effects in the applied health sciences. Health Services and Outcomes Research Methodology, 2007, 7, 159-179.	1.8	37
52	Response to Pazderka and Schroeder. Healthcare Policy, 2007, 2, 95-96.	0.6	0
53	Response to pazderka and schroeder. Healthcare Policy, 2007, 2, 95-6.	0.6	0
54	The effect of pharmaceutical patent term length on research and development and drug expenditures in Canada. Healthcare Policy, 2007, 2, 63-84.	0.6	8

PAUL GROOTENDORST

#	Article	IF	CITATIONS
55	Dental insurance, income and the use of dental care in Canada. Journal of the Canadian Dental Association, 2007, 73, 57.	0.6	54
56	A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee. Journal of Rheumatology, 2007, 34, 534-42.	2.0	42
57	A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. Health Economics (United Kingdom), 2006, 15, 735-742.	1.7	23
58	Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis. Journal of Health Services Research and Policy, 2006, 11, 13-20.	1.7	20
59	Distributional effects of 'general population' prescription drug programs in Canada. Canadian Journal of Economics, 2005, 38, 128-148.	1.2	13
60	Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada. Health Economics (United Kingdom), 2005, 14, 909-923.	1.7	59
61	Disclosure of Physician Prescribing Information and Prescription Drug Costs: Evidence from Saskatchewan. Journal of Pharmaceutical Marketing and Management, 2005, 17, 61-87.	0.1	1
62	The Economics of Cross-Border Trade in Pharmaceuticals. Journal of Pharmaceutical Marketing and Management, 2005, 16, 99-109.	0.1	1
63	Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence. International Journal of Health Services, 2004, 34, 101-122.	2.5	160
64	The Economics of Cross-Border Trade in Pharmaceuticals: Theory and Evidence. Journal of Pharmaceutical Marketing and Management, 2004, 16, 99-109.	0.1	1
65	An empirical analysis of milk addiction. Journal of Health Economics, 2004, 23, 1117-1133.	2.7	118
66	Net Health Plan Savings From Reference Pricing for Angiotensin-Converting Enzyme Inhibitors in Elderly British Columbia Residents. Medical Care, 2004, 42, 653-660.	2.4	44
67	A Review of the Comprehensiveness of Provincial Drug Coverage for Canadian Seniors. Canadian Journal on Aging, 2003, 22, 33-44.	1.1	5
68	Validity of self-reported prescription drug insurance coverage. Health Reports, 2003, 14, 35-46.	0.8	6
69	The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada. Journal of Health Economics, 2002, 21, 805-826.	2.7	21
70	On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. Health Policy, 2001, 55, 97-109.	3.0	32
71	Censoring in statistical models of health status: what happens when one can do better than '1'. , 2000, 9, 911-914.		19